share_log

康希諾生物:自願公告 - 重組脊髓灰質炎疫苗於印度尼西亞獲得臨床試驗批准

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - GRANT AGREEMENT OF RECOMBINANT POLIOMYELITIS VACCINE AND RELATED COMBINED VACCINE PROJECT

HKEX ·  Oct 9 16:31

Summary by Moomoo AI

康希诺生物宣布,其研發中的候選疫苗CS-2036,已進入I/II期臨床試驗階段。該疫苗採用VLP(病毒樣粒子)技術平台開發,旨在針對多種病原體提供保護。康希诺生物的CEO Xuefeng YU和首席科學官Shou Bai CHAO將領導這項臨床試驗。試驗預計將於2024年10月9日完成。
康希诺生物宣布,其研發中的候選疫苗CS-2036,已進入I/II期臨床試驗階段。該疫苗採用VLP(病毒樣粒子)技術平台開發,旨在針對多種病原體提供保護。康希诺生物的CEO Xuefeng YU和首席科學官Shou Bai CHAO將領導這項臨床試驗。試驗預計將於2024年10月9日完成。
CanSino Biologics announced that its in-development candidate vaccine CS-2036 has entered the Phase I/II clinical trial stage. The vaccine is developed using VLP (virus-like particle) technology platform, aiming to provide protection against multiple pathogens. CanSino Biologics' CEO Xuefeng YU and Chief Scientific Officer Shou Bai CHAO will lead this clinical trial. The trial is expected to be completed on October 9, 2024.
CanSino Biologics announced that its in-development candidate vaccine CS-2036 has entered the Phase I/II clinical trial stage. The vaccine is developed using VLP (virus-like particle) technology platform, aiming to provide protection against multiple pathogens. CanSino Biologics' CEO Xuefeng YU and Chief Scientific Officer Shou Bai CHAO will lead this clinical trial. The trial is expected to be completed on October 9, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more